Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
January 31, 2023

Nanoscope’s Stargardt disease treatment gets fast track designation

Nanoscope Therapeutics has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) for the treatment of Stargardt disease to improve visual function.

The firm expects to receive the six-month data from the STARLIGHT trial in Q1 2022. Credit: Paul Diaconu from Pixabay.